| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 138 |
| 1 | SULFASALAZINE | 138 |
| 2 | INFLIXIMAB | 137 |
| 3 | METHOTREXATE SODIUM | 137 |
| 4 | ETANERCEPT | 136 |
| 5 | METHOTREXATE | 133 |
| 6 | TOCILIZUMAB | 133 |
| 7 | ABATACEPT | 132 |
| 8 | LEFLUNOMIDE | 132 |
| 9 | RITUXIMAB | 118 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FEBUXOSTAT | 82 | 0.0090 |
| 1 | COLCHICINE | 80 | 0.0043 |
| 2 | IBUPROFEN AND DIPHENHYDRAMINE CITRATE | 60 | 0.0030 |
| 3 | TETRACAINE HYDROCHLORIDE | 1 | 0.0028 |
| 4 | SULFASALAZINE | 138 | 0.0027 |
| 5 | GOLD | 8 | 0.0023 |
| 6 | DEXLANSOPRAZOLE | 72 | 0.0021 |
| 7 | TOCILIZUMAB | 133 | 0.0020 |
| 8 | RISEDRONATE SODIUM | 44 | 0.0020 |
| 9 | LEFLUNOMIDE | 132 | 0.0018 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 141 |
| 1 | Aminosalicylate [EPC] | 138 |
| 2 | Folate Analog Metabolic Inhibitor [EPC] | 133 |
| 3 | Interleukin-6 Receptor Antagonist [EPC] | 133 |
| 4 | Antirheumatic Agent [EPC] | 132 |
| 5 | Selective T Cell Costimulation Modulator [EPC] | 132 |
| 6 | CD20-directed Cytolytic Antibody [EPC] | 118 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 90 |
| 8 | Corticosteroid [EPC] | 84 |
| 9 | Interleukin-12 Antagonist [EPC] | 82 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Alkaloid [EPC] | 80 | 0.0043 |
| 1 | Interleukin-6 Receptor Antagonist [EPC] | 133 | 0.0018 |
| 2 | Antirheumatic Agent [EPC] | 132 | 0.0018 |
| 3 | Aminosalicylate [EPC] | 138 | 0.0017 |
| 4 | Selective T Cell Costimulation Modulator [EPC] | 132 | 0.0015 |
| 5 | Interleukin-12 Antagonist [EPC] | 82 | 0.0014 |
| 6 | Interleukin-23 Antagonist [EPC] | 82 | 0.0012 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 118 | 0.0008 |
| 8 | Standardized Chemical Allergen [EPC] | 8 | 0.0008 |
| 9 | Xanthine Oxidase Inhibitor [EPC] | 82 | 0.0007 |